Research programme: lung disorder therapeutics - Lung Therapeutics/University of Texas Health Sciences Center at Tyler

Drug Profile

Research programme: lung disorder therapeutics - Lung Therapeutics/University of Texas Health Sciences Center at Tyler

Alternative Names: LTI-02; LTI-03; scuPA; Single chain urokinase plasminogen activator

Latest Information Update: 31 Oct 2014

Price : $50

At a glance

  • Originator Lung Therapeutics; University of Texas at Tyler
  • Class Plasminogen activator enzymes; Serine endopeptidases
  • Mechanism of Action Fibrinolytic agents; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lung injury
  • Research Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Oct 2014 Early research in Idiopathic pulmonary fibrosis in USA (unspecified route)
  • 28 Oct 2014 Preclinical trials in Acute lung injury in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top